Novo Nordisk A/S Common Stock (NY:NVO)

Everyone's ganging up on Hims & Hers stock this week.

Topics Intellectual Property Lawsuit

Why Hims & Hers Stock Just Got Destroyed ↗

February 09, 2026

The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash

Topics Lawsuit

February 09, 2026

The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to...

HIMS Stock Plunges 10% After Hours: FDA Chief Warns Of ‘Swift Action’ On Copycat Drugs After Novo Semaglutide Knockoff Launch ↗

Topics Intellectual Property Lawsuit

February 05, 2026

According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy.

FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains ↗

February 09, 2026

Novo Nordisk just did Eli Lilly stock a huge favor.

Topics Lawsuit

Why Eli Lilly Stock Just Popped ↗

February 09, 2026

The GLP-1 Gold Rush Hits a Wall: Hims & Hers Shares Crater After Abrupt Oral Wegovy U-Turn

Topics Lawsuit

February 09, 2026

The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of...

Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks ↗

Topics Earnings Intellectual Property

February 09, 2026

Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.

HIMS Stock In Turmoil: Retail Bulls Bet On Rebound, Skeptics See Bloodbath After Compounded Weight-Loss Pill Halt ↗

Topics Intellectual Property Lawsuit

February 08, 2026

Retail bulls pointed to similar price levels during high short interest in late 2024 and said ending compounded sales removes the risk of a costly legal fight.

Novo Nordisk has good news and bad news to report in its fourth-quarter 2025 earnings.

Topics Intellectual Property Law Enforcement

Novo Nordisk Plunges Nearly 15% After Earnings. Here's What Investors Need to Know. ↗

February 08, 2026

Medicare Changes in 2026 Every Retiree Needs to Know: The Good, the Bad, and the Ugly ↗

February 08, 2026

Retirees should brace themselves for both positive and negative changes to Medicare this year.

Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.

Topics Economy Government Retirement

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 07, 2026

HIMS Stock Slumps After-Hours On Regulatory Scrutiny On Heels Of Compounded Wegovy Pill Launch ↗

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗

February 06, 2026

Via MarketBeat

February 06, 2026

The U.S. Food and Drugs Administration Commissioner Martin A Makary announced the agency’s intent to restrict the ingredients used by Hims as alternatives to FDA-approved drugs.

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

February 06, 2026

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83...

The market for obesity drugs may soon reach almost $100 billion.

Topics Earnings Economy

Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore ↗

February 06, 2026

The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral...

The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market

February 06, 2026

The drugmaker is facing pricing pressures on its weight loss medications.

Topics Economy Intellectual Property Law Enforcement

Why Shares of Novo Nordisk Stock Collapsed This Week ↗

February 06, 2026

The Trillion-Dollar Divergence: Eli Lilly Hits Milestone While Novo Nordisk Faces 'Supply Chain Reset'

February 06, 2026

The global race for obesity market dominance reached a historic turning point this week as Eli Lilly and Company (NYSE: LLY) officially crossed the $1 trillion market capitalization threshold,...

The market is in an unforgiving mood.

Topics Economy

Why Did AMD, Uber, and Novo Nordisk Stock Crash This Week? ↗

February 06, 2026

As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade...

The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance

February 06, 2026

Via Finterra

Topics Economy Government Intellectual Property

Eli Lilly Stock Has Over 20% Upside, Analysts Say: Retail Seeks Pharma 'Safe Haven' As FDA Targets GLP-1 Copycats ↗

February 05, 2026

The stock’s rise followed FDA Commissioner Marty Makary's warning against companies marketing illegal copycat drugs.

Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. ↗

Topics Fraud Law Enforcement

February 05, 2026

There's another fight brewing around GLP-1 drugs -- this time on the delivery side.

The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of...

Trade War 2.0: 25% Tariffs on Chips, Cars, and Medicine Reshape the Global Supply Chain

February 05, 2026

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

Topics Artificial Intelligence Earnings Economy

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...

Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.

Topics Earnings Economy

Hims & Hers Takes On Novo Nordisk: What We Know Right Now ↗

February 05, 2026

This software firm delivers AI-driven cloud platforms for enterprise customer engagement and compliance across global markets.

OAK Family Advisors Sells $4 Million of NICE Stock ↗

February 05, 2026

The stock price has climbed in the triple digits over three years.

Topics Artificial Intelligence Regulatory Compliance

Eli Lilly Just Delivered Fantastic News to Shareholders ↗

February 05, 2026

Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗

Topics Government

February 05, 2026

The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes...

As the first week of February 2026 unfolds, a dramatic shift in investor sentiment has split the U.S. stock market. While technology and artificial intelligence stocks have faced a sharp pullback, the...

Topics Economy Government World Trade

Healthcare Titans Propel Dow to Record Highs as GLP-1 Sales Spark Major Market Rotation

February 05, 2026